** Shares of gene therapy maker bluebird bio BLUE.O fall 38.6% to $4.32 premarket

** Co says it would be taken private by Carlyle CG.O and SK Capital Partners

** BLUE stockholders will receive $3/shr in cash, implying an equity value of around $29.2 mln

** The offer is at an over 57% discount from the stock's last close of $7.04

** Investment firms have also offered additional $6.84/shr, contingent upon achieving certain sales milestones, which represents a payment of about $66.5 mln

** BLUE fell 69.8% in 2024

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))